Item 1.01 Entry Into a Material Definitive Agreement.
On September 30, 2021, Emergent BioSolutions Inc. (including its wholly-owned
subsidiaries, "Emergent"), through its wholly-owned subsidiary, Emergent Product
Development Gaithersburg Inc., received a contract modification ("Modification
No. 11") to the AV7909 development and procurement contract with the Biomedical
Advanced Research and Development Authority ("BARDA"), a component of the Office
of the Assistant Secretary for Preparedness and Response, ("ASPR"), an agency of
the U.S. Department of Health and Human Services. Modification No. 11 seeks to
procure additional doses of AV7909 (anthrax vaccine adsorbed with adjuvant) for
delivery into the Strategic National Stockpile, valued at approximately $399
million, with deliveries over the next 18 months.
The preceding description of the modification described herein does not purport
to be complete and is qualified in its entirety by reference to the full text of
the actual modification. The modification, with relevant redactions to protect
confidential and sensitive information, is expected to be filed as an exhibit to
Emergent's Quarterly Report on Form 10-Q for the fiscal quarter ended September
30, 2021.
© Edgar Online, source Glimpses